Spain’s Health System Rejects Alzheimer Drug Funding
Eli Lilly is arguing with the Spanish government about money for Alzheimer’s drugs. The government won’t pay for new treatments like Kisunla and Leqembi. This is causing problems for people with Alzheimer’s in Spain.
The Spanish Ministry of Health has stopped funding medications used to treat early Alzheimer’s. These drugs, including lecanemab and donanemab, were seen as promising. The Interministerial Commission decided not to fund them. Many people around the world have Alzheimer’s, about 50 million. This situation shows how difficult it is to get money for new medicines.
Summarized from the sources above. Read the originals for the full story.
Highlights
Funding Dispute Emerges
Eli Lilly and Spain’s Ministry of Health are arguing about money for Alzheimer’s treatments.
Government Refuses Funding
The Spanish Ministry of Health will not pay for drugs like Kisunla and Leqembi.
Drugs Show Promise
Lecanemab and donanemab have shown they can slow Alzheimer’s progression.
Global Alzheimer’s Impact
Alzheimer’s affects 50 million people worldwide.
Commission’s Negative Decision
The Interministerial Commission decided not to fund the new drugs.